Document Detail

Chlorogenic acid, a polyphenolic compound, treats mice with septic arthritis caused by Candida albicans.
MedLine Citation:
PMID:  18760384     Owner:  NLM     Status:  MEDLINE    
There has been an increasing number of studies concerning the multiple biological activities of polyphenolic compounds. In this present study, we determined the effect of chlorogenic acid (CRA), a polyphenolic compound, on septic arthritis caused by Candida albicans, a major etiological agent that causes fungal arthritis. To induce septic arthritis, an emulsified mixture of C. albicans cell wall and Complete Freund's Adjuvant (CACW/CFA) was injected into BALB/c mice via hind footpad route once a day for 3 days. Twenty-four hours after the final injection, in order to determine CRA effect, mice having the swollen footpad were given CRA (1 mg/dose/mouse) intraperitoneally every other day three times. The footpad edema was measured for 15 days. Results showed that the CRA treatment reduced approximately 40% of the edema at the peak of septic arthritis (P<0.05). This anti-arthritic activity appeared to be mediated by a complete inhibition of nitric oxide (NO) production from macrophages and suppression of T-cells proliferation. Furthermore, CRA also inhibited growth of C. albicans yeast cells (P<0.01) and caused no hemolysis. These data indicate that CRA, which has antifungal and anti-arthritic effects, can safely be administered into the blood circulation for treatment of septic arthritis due to C. albicans. In addition, in respect to antiseptic arthritis, it can be suggested that the anti-candidal effect of CRA may be helpful as an all-in-one treatment of the candidal arthritis.
Jue-Hee Lee; Ji Hye Park; Yeong Shik Kim; Yongmoon Han
Related Documents :
19722074 - Present situation and new strategies for chagas disease chemotherapy: a proposal.
2695834 - Design of liposomes to improve delivery of amphotericin-b in the treatment of aspergill...
12493804 - In vitro and in vivo anticryptococcal activities of a new pyrazolo-isothiazole derivative.
23358334 - Evaluation and examination of accuracy for the conversion factors of effective dose per...
16367894 - Efficacy and safety of high-dose cabergoline in parkinson's disease.
14522434 - Anti-inflammatory and analgesic properties of the leaf extracts and essential oil of la...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-08-27
Journal Detail:
Title:  International immunopharmacology     Volume:  8     ISSN:  1567-5769     ISO Abbreviation:  Int. Immunopharmacol.     Publication Date:  2008 Dec 
Date Detail:
Created Date:  2008-10-20     Completed Date:  2008-12-03     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100965259     Medline TA:  Int Immunopharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  1681-5     Citation Subset:  IM    
Department of ImmunoMicrobiology, College of Pharmacy/Dongduk Women's University, 23-1 Wolgok-Dong, Seongbuk-Gu, Seoul 136-714, Republic of Korea.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Arthritis, Infectious / drug therapy*
Candida albicans / drug effects*
Candidiasis / drug therapy*
Chlorogenic Acid / pharmacology*
Hemolysis / drug effects
Lymphocyte Activation / drug effects
Macrophages / metabolism
Mice, Inbred BALB C
Nitric Oxide / biosynthesis
Reg. No./Substance:
10102-43-9/Nitric Oxide; 327-97-9/Chlorogenic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pyrogallol, an active compound from the medicinal plant Emblica officinalis, regulates expression of...
Next Document:  Contrasting effects of estradiol and progesterone on respiratory pattern and hypoxic ventilatory res...